EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System

Carol J Levy, Daniel Carlow, Dan Swift, Rana Rittgers-Simonds, Noelle N Gronroos, Valery Walker, Erin K Buysman, Gregory Forlenza

Diabetes Technology & Therapeutics · 2025

DOI: 10.1177/15209156251395014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Technology & Therapeutics, 2025. Verfasst von Carol J Levy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes, and Metabolism, The Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Glycated Hemoglobin, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Insulin Infusion Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The Omnipod® 5 Automated Insulin Delivery (AID) System is the first wearable, on-body, tubeless AID system in the United States. Clinical trials have demonstrated hemoglobin A1C (HbA1c) improvements with Omnipod 5 use. The aim of the study was to evaluate HbA1c changes after initiating Omnipod 5 in a real-world setting. METHODS: This retrospective study utilized commercial and Medicare Advantage with Part D enrollees' claims data from the Optum Research Database between August 1, 2021, and December 31, 2023. The study included individuals diagnosed with type 1 diabetes (T1D) or type 2 diabetes (T2D) who initiated Omnipod 5. Participants were required to have continuous enrollment for 12 months pre- and post-initiation and at least two medical claims for diabetes during these periods. Demographic and clinical characteristics were measured at the index date, and HbA1c levels were compared pre- and post-initiation of Omnipod 5. RESULTS: The final sample included 2,504 users, with 792 having pre- and post-initiation HbA1c results. The mean age was 54 years; 48% were enrolled in Medicare Advantage, 90% had prior continuous glucose monitoring, and 64% had prior pump therapy. A mean reduction in HbA1c of 0.4% was observed (P < 0.001); mean reductions were 0.4% and 0.5% among those with type 1 and type 2 diabetes, respectively. Among 135 users with pre-initiation HbA1c levels ≥9%, a reduction of 1.4% was noted (P < 0.001). Pre-initiation, 31% achieved the American Diabetes Association (ADA) target of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycated HemoglobinDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Insulin Infusion SystemsInsulinHypoglycemic AgentsHumansRetrospective StudiesMaleFemaleMiddle AgedUnited StatesAgedAdultBlood Glucose

Stichwörter der Autor:innen

HEDISHbA1cOmnipodautomated insulin deliverydiabetes

Substanzen

Glycated HemoglobinInsulinHypoglycemic Agentshemoglobin A1c protein, humanBlood Glucose

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes, and Metabolism, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Insulet Corporation, Acton, Massachusetts, USA.
  • Optum, Eden Prairie, Minnesota, USA.
  • Department of Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Zitieren

APA

Levy, C. J., Carlow, D., Swift, D., Rittgers-Simonds, R., Gronroos, N. N., Walker, V., Buysman, E. K., & Forlenza, G. (2025). Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System. Diabetes Technology & Therapeutics. https://doi.org/10.1177/15209156251395014

Vancouver

Levy CJ, Carlow D, Swift D, Rittgers-Simonds R, Gronroos NN, Walker V, et al. Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System. Diabetes Technology & Therapeutics. 2025. doi:10.1177/15209156251395014

BibTeX
@article{Levy2025,
  author = {Levy, Carol J and Carlow, Daniel and Swift, Dan and Rittgers-Simonds, Rana and Gronroos, Noelle N and Walker, Valery and Buysman, Erin K and Forlenza, Gregory},
  title = {Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System},
  journal = {Diabetes Technology & Therapeutics},
  year = {2025},
  doi = {10.1177/15209156251395014}
}
Kostenlos starten →